| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA738: Berotralstat for preventing acute attacks of hereditary angioedema |
|
Medicine details |
|
| Medicine name | berotralstat (Orladeyo®) |
| Formulation | 150 mg hard capsules |
| Reference number | 4796 |
| Indication | Routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older |
| Company | BioCryst Pharmaceuticals Inc |
| BNF chapter | Respiratory system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/03/2021 |
| NICE guidance | TA738: Berotralstat for preventing acute attacks of hereditary angioedema |